结直肠癌中新出现的 HER2 标志：揭示未来治疗算法的关键？

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-09-18 DOI:10.1016/j.critrevonc.2024.104515

Jacopo Venturini , Giulia Massaro , Daniele Lavacchi , Daniele Rossini , Serena Pillozzi , Enrico Caliman , Elisa Pellegrini , Lorenzo Antonuzzo

{"title":"结直肠癌中新出现的 HER2 标志：揭示未来治疗算法的关键？","authors":"Jacopo Venturini , Giulia Massaro , Daniele Lavacchi , Daniele Rossini , Serena Pillozzi , Enrico Caliman , Elisa Pellegrini , Lorenzo Antonuzzo","doi":"10.1016/j.critrevonc.2024.104515","DOIUrl":null,"url":null,"abstract":"<div><div>Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations. Albeit its controversial prognostic role, preclinical and clinical data indicate HER2 as a negative predictive biomarker of response to anti-EGFR therapies. Tissue and plasma-based NGS testing, could permit a precise identification of this resistance mechanism both at baseline and during treatment, thus guiding decision-making. Furthermore, promising results come from completed and ongoing randomized trials, testing HER2 as an actionable target. In this review, we discuss the available evidence on HER2 targeting in advanced CRC, analyzing its possible future role in the treatment algorithm.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104515"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002580/pdfft?md5=eab9df80d555f02399a513bf0b2e25d1&pid=1-s2.0-S1040842824002580-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?\",\"authors\":\"Jacopo Venturini , Giulia Massaro , Daniele Lavacchi , Daniele Rossini , Serena Pillozzi , Enrico Caliman , Elisa Pellegrini , Lorenzo Antonuzzo\",\"doi\":\"10.1016/j.critrevonc.2024.104515\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations. Albeit its controversial prognostic role, preclinical and clinical data indicate HER2 as a negative predictive biomarker of response to anti-EGFR therapies. Tissue and plasma-based NGS testing, could permit a precise identification of this resistance mechanism both at baseline and during treatment, thus guiding decision-making. Furthermore, promising results come from completed and ongoing randomized trials, testing HER2 as an actionable target. In this review, we discuss the available evidence on HER2 targeting in advanced CRC, analyzing its possible future role in the treatment algorithm.</div></div>\",\"PeriodicalId\":11358,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\"204 \",\"pages\":\"Article 104515\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1040842824002580/pdfft?md5=eab9df80d555f02399a513bf0b2e25d1&pid=1-s2.0-S1040842824002580-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1040842824002580\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002580","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

结直肠癌（CRC）对全球健康构成威胁，是全球癌症相关死亡的第二大原因。靶向疗法为转移期癌症带来了新希望，因为转移期癌症的预后历来很差。约有 5% 的转移性 CRC（mCRC）患者存在人类表皮生长受体 2（HER2）过表达，包括基因扩增和点突变。尽管其预后作用存在争议，但临床前和临床数据表明，HER2 是抗 EGFR 疗法反应的阴性预测生物标志物。基于组织和血浆的 NGS 检测可以在基线和治疗过程中精确识别这种耐药机制，从而为决策提供指导。此外，已完成和正在进行的随机试验也取得了令人鼓舞的结果，这些试验将 HER2 作为一个可操作的靶点进行测试。在本综述中，我们将讨论晚期 CRC 中 HER2 靶向治疗的现有证据，分析其在治疗算法中未来可能发挥的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?

Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations. Albeit its controversial prognostic role, preclinical and clinical data indicate HER2 as a negative predictive biomarker of response to anti-EGFR therapies. Tissue and plasma-based NGS testing, could permit a precise identification of this resistance mechanism both at baseline and during treatment, thus guiding decision-making. Furthermore, promising results come from completed and ongoing randomized trials, testing HER2 as an actionable target. In this review, we discuss the available evidence on HER2 targeting in advanced CRC, analyzing its possible future role in the treatment algorithm.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.